Processing

Please wait...

Settings

Settings

1. WO1996004313 - POLYSPECIFIC IMMUNOCONJUGATES AND ANTIBODY COMPOSITES FOR TARGETING THE MULTIDRUG RESISTANT PHENOTYPE

Publication Number WO/1996/004313
Publication Date 15.02.1996
International Application No. PCT/US1995/009491
International Filing Date 01.08.1995
Chapter 2 Demand Filed 01.03.1996
IPC
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 51/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
10Antibodies or immunoglobulins; Fragments thereof
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/6898
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6891Pre-targeting systems involving an antibody for targeting specific cells
6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
6898using avidin- or biotin-conjugated antibodies
A61K 51/1084
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
1003not used, see subgroups
1084the antibody being a hybrid immunoglobulin
A61K 51/1093
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
1093conjugates with carriers being antibodies
B82Y 5/00
BPERFORMING OPERATIONS; TRANSPORTING
82NANOTECHNOLOGY
YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
5Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applicants
  • IMMUNOMEDICS, INC. [US/US]; 300 American Road Morris Plains, NJ 07950, US
Inventors
  • GOLDENBERG, David, M.; US
Agents
  • SAXE, Bernhard, D. ; Foley & Lardner Suite 500 3000 K Street, N.W. Washington, DC 20007-5109, US
Priority Data
08/286,43005.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) POLYSPECIFIC IMMUNOCONJUGATES AND ANTIBODY COMPOSITES FOR TARGETING THE MULTIDRUG RESISTANT PHENOTYPE
(FR) IMMUNOCONJUGUES POLYSPECIFIQUES ET COMPOSITES D'ANTICORPS PERMETTANT LE CIBLAGE DU PHENOTYPE MULTIPHARMACORESISTANT
Abstract
(EN)
Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.
(FR)
La présente invention concerne des immunoconjugués polyspécifiques et des composites d'anticorps se liant à une protéine multipharmacotransporteuse et un antigène associé à un agent tumoral ou infectieux et permettant de venir à bout d'un phénotype multipharmacorésistant. Ces immunoconjugués et composites sont également utilisables en diagnostic pour déterminer si l'échec de la chimiothérapie est dû à la présence de cellules tumorales multipharmacorésistantes, de cellules multipharmacorésistantes infectées par le VIH, ou d'agents infectieux multipharmacorésistants.
Latest bibliographic data on file with the International Bureau